Epistaxis is one of the most common and debilitating symptoms of hereditary hemorrhagic telangiectasia (HHT), significantly impacting patients’ quality of life. While various medical and surgical interventions exist for managing epistaxis in patients with HHT, patients with moderate to severe epistaxis are high health-care utilizers who frequently need surgical treatment.
Objective
To compare the efficacy, complications, and patient-reported outcomes for common surgical interventions utilized in treating epistaxis in patients with HHT
Methods
Studies were identified in PubMed, Embase, Scopus, Redalyc, and LILACS databases and uploaded to Covidence. A systematic review following PRISMA guidelines was conducted on studies evaluating outcomes in adults with HHT with moderate to severe epistaxis who had undergone surgical interventions. We compared the respective outcomes for pre-operative and post-operative epistaxis severity/intensity, need for further interventions or transfusions, estimated blood loss, length of surgery, complications, and patient satisfaction.
Results
Twenty studies with a total of 546 patients were included. The most common surgeries studied were nasal closure and laser photocoagulation. Seven studies recorded the change in epistaxis severity score and observed a significant reduction postoperatively (3.91, [95% CI 2.73-5.09]). Eleven studies found a decrease in the number of transfusions and a rise in hemoglobin levels post-operatively. Common complications reported were partial dehiscence of a nasal closure, septal perforation, and continued bleeding requiring re-operation. Most patients report improved quality of life and satisfaction with surgical intervention.
Conclusion
Surgery can significantly reduce the severity of epistaxis in patients with HHT and improve quality of life. Further studies should focus on head-to-head comparisons of procedures and standardization of outcome measures.
ShovlinCLGuttmacherAEBuscariniE, et al.Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu–Osler–Weber syndrome). Am J Med Genet.2000;91(1):66–67.
2.
Hasan AlbitarHAVan HoutenHSangaralinghamLR, et al.Healthcare utilization and costs associated with hereditary hemorrhagic telangiectasia patients in a large US claims database. Mayo Clin Proc Innov Qual Outcomes. 2021;5(1):55–64.
3.
HoagJBTerryPMitchellSRehDMerloCA. An epistaxis severity score for hereditary hemorrhagic telangiectasia. Laryngoscope.2010;120(4):838–843.
4.
GeisthoffUWSeyfertUTKüblerMBiegBPlinkertPKKönigJ. Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid—a double-blind placebo-controlled cross-over phase IIIB study. Thromb Res. 2014;134(3):565–571.
5.
Al-SamkariHAlbitarHAOlitskySEClancyMSIyerVN. An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia. Haemophilia. 2020;26(6):1038–1045.
6.
WoodardTDYappel-SinkkoKBWangXMccraeKRParambilJG. Sclerotherapy versus cautery/laser treatment for epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope.2022;132(5):920–925.
7.
MinamiKHajiT. Intranasal topical estrogen in the management of epistaxis in hereditary hemorrhagic telangiectasia. Acta Otolaryngol.2016;136(5):528–531.
8.
VaseP. Estrogen treatment of hereditary hemorrhagic telangiectasia. Acta Med Scand.1981;209(1-6):393–396.
9.
FaviaGTempestaALimongelliLSuppressaPSabbàCMaioranoE. Diode laser treatment and clinical management of multiple oral lesions in patients with hereditary haemorrhagic telangiectasia. Br J Oral Maxillofac Surg. 2016;54(4):379–383.
10.
FellerCNAdamsJAFriedlandDRPoetkerDM. Duration of effectiveness of coblation for recurrent epistaxis in hereditary hemorrhagic telangiectasia. Am J Otolaryngol. 2022;43(3):103409.
11.
HarveyRJKanagalingamJLundVJ. The impact of septodermoplasty and potassium-titanyl-phosphate (KTP) laser therapy in the treatment of hereditary hemorrhagic telangiectasia-related epistaxis. Am J Rhinol. 2008;22(2):182–187.
12.
AndersenJHKjeldsenAD. Patient-recorded benefit from nasal closure in a Danish cohort of patients with hereditary haemorrhagic telangiectasia. Eur Arch Oto-Rhino-Laryngol.2020;277(3):791–800.
13.
AbiriAGoshtasbiKMaducdocMSahyouniRWangMBKuanEC. Laser-assisted control of epistaxis in hereditary hemorrhagic telangiectasia: A systematic review. Lasers Surg Med. 2020;52(4):293–300.
14.
ChitsuthipakornWHoangMPKanjanawaseeDSeresirikachornKSnidvongsK. Treatments of epistaxis in hereditary hemorrhagic telangiectasia: Systematic review and network meta-analysis. Curr Allergy Asthma Rep. 2023;23(12):689–701.
15.
HoffmanHAshok KumarARaventhiranathanNMasoudHEGouldGC. Endovascular embolization for the treatment of epistaxis: Systematic review and meta-analysis. Interv Neuroradiol. 2023;29(2):172–182.
16.
PageMJMcKenzieJEBossuytPM, et al.The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Br Med J.2021;372(1):n71. doi:https://doi.org/10.1136/bmj.n71
17.
MoherDLiberatiATetzlaffJAltmanDG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009;6(7):e1000097.
18.
FaughnanMEMagerJJHettsSW, et al.Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia. Ann Intern Med. 2020;173(12):989–1001.
19.
HowickJ, Chalmers I, Glasziou P, Greenhalgh T, Heneghan C, Liberati A, et al.The Oxford Levels of Evidence 2. Oxford Centre for Evidence-Based Medicine; 2011.
20.
SterneJACSavovićJPageMJ, et al.Rob 2: A revised tool for assessing risk of bias in randomised trials. Br Med J.2019;366(4898):1-7. doi:https://doi.org/10.1136/bmj.l4898
21.
SterneJAHernánMAReevesBC, et al.ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. Br Med J.2016;355(4919):1. doi:https://doi.org/10.1136/bmj.i4919
22.
MunnZBarkerTHMoolaS, et al.Methodological quality of case series studies: An introduction to the JBI critical appraisal tool. JBI Evid Synth. 2020;18(10):2127–2133.
23.
HigginsJTJChandlerJThomasJ, et al.Cochrane Handbook for Systematic Reviews of Interventions Version 6.4. Cochrane, 2023.
24.
BerglerWSadickHGotteKRiedelFHörmannK. Topical estrogens combined with argon plasma coagulation in the management of epistaxis in hereditary hemorrhagic telangiectasia. Ann Otol Rhinol Laryngol. 2002;111(3 Pt 1):222–228.
25.
HitchingsAELennoxPALundVJHowardDJ. The effect of treatment for epistaxis secondary to hereditary hemorrhagic telangiectasia. Am J Rhinol. 2005;19(1):75–78.
26.
IchimuraKTanakaHYamamotoYNakamuraK. Nasal dermoplasty for Japanese hereditary hemorrhagic telangiectasia. Auris Nasus Larynx. 2006;33(4):423–428.
27.
IchimuraKKikuchiHImayoshiSYamauchiTIshikawaK. Are patients with severe epistaxis caused by hereditary hemorrhagic telangiectasia satisfied with nostril closure surgery?Auris Nasus Larynx. 2012;39(1):59–64.
28.
PagellaFSeminoLOlivieriC, et al.Treatment of epistaxis in hereditary hemorrhagic telangiectasia patients by argon plasma coagulation with local anesthesia. Am J Rhinol. 2006;20(4):421–425.
29.
RicherSLGeisthoffUWLivadaN, et al.The Young’s procedure for severe epistaxis from hereditary hemorrhagic telangiectasia. Am J Rhinol Allergy. 2012;26(5):401–404.
30.
RotenbergBNoyekSChinCJ. Radiofrequency ablation for treatment of hereditary hemorrhagic telangiectasia lesions: “How I do it”. Am J Rhinol Allergy. 2015;29(3):226–227.
31.
FiorellaMLRossDHendersonKJWhiteRI. Outcome of septal dermoplasty in patients with hereditary hemorrhagic telangiectasia. Laryngoscope.2005;115(2):301–305.
32.
HochetBAchardSMaillardHMortuaireG. Retrospective analysis of submucosal radiofrequency procedure for the treatment of nasal bleeding in 44 patients with hereditary haemorrhagic telangiectasia. Clin Otolaryngol.2019;44(6):1138–1141.
33.
LukLMaceJCBhandarkarNDSautterNB. Comparison of electrosurgical plasma coagulation and potassium-titanyl-phosphate laser photocoagulation for treatment of hereditary hemorrhagic telangiectasia-related epistaxis. Int Forum Allergy Rhinol.2014;4(8):640–645.
34.
LundVJDarbyYRimmerJAminMHusainS. Nasal closure for severe hereditary haemorrhagic telangiectasia in 100 patients. The Lund modification of the Young’s procedure: A 22-year experience. Rhinol J. 2017;55(2):135–141.
35.
MattiEMaioranoENacuB, et al.Lamine settali in silicone nel trattamento dell’epistassi ricorrente nei pazienti con HHT: L’esperienza di un centro di riferimento nazionale. Acta Otorhinolaryngol Ital.2023;43(2 (Suppl. 1)):S28–S33.
36.
MortuaireGBouteOHatronPYChevalierD. Pilot study of submucosal radiofrequency for epistaxis in hereditary hemorrhagic telangiectasia. Rhinol J. 2013;51(4):355–360.
37.
PagellaFMattiEChuF, et al.Argon plasma coagulation is an effective treatment for hereditary hemorrhagic telangiectasia patients with severe nosebleeds. Acta Otolaryngol.2013;133(2):174–180.
38.
PyneJMMurraySKellyBCSongJSRosvallBRCôtéDWJ. Surgiflo® hemostatic matrix versus NasoPore® nasal packing following potassium titanyl phosphate laser surgery for hereditary hemorrhagic telangiectasia: A randomized controlled trial. Laryngoscope Investig Otolaryngol. 2023;8(2):328–334.
39.
ThomsonRSMolinNLWhiteheadKJ, et al.The effects of nasal closure on quality of life in patients with hereditary hemorrhagic telangiectasia. Laryngoscope Investig Otolaryngoly. 2018;3(3):178–181.
40.
TimminsBHHunterBNWilsonKFWardPD. Treatment of severe refractory epistaxis in hereditary hemorrhagic telangiectasia using a two-flap nasal closure method. Int Forum Allergy Rhinol.2016;6(5):544–548.
41.
WirschingKECHaubnerFKühnelTS. Influence of temporary nasal occlusion (tNO) on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia (HHT). Eur Arch Oto-Rhino-Laryngol.2017;274(4):1891–1896.
42.
YinLXRehDDHoagJB, et al.The minimal important difference of the epistaxis severity score in hereditary hemorrhagic telangiectasia. Laryngoscope.2016;126(5):1029–1032.
43.
MerloCAYinLXHoagJBMitchellSERehDD. The effects of epistaxis on health-related quality of life in patients with hereditary hemorrhagic telangiectasia. Int Forum Allergy Rhinol.2014;4(11):921–925.
44.
KritharisAAl-SamkariHKuterDJ. Hereditary hemorrhagic telangiectasia: Diagnosis and management from the hematologist’s perspective. Haematologica. 2018;103(9):1433–1443.
45.
ChinCJRotenbergBWWitterickIJ. Epistaxis in hereditary hemorrhagic telangiectasia: An evidence based review of surgical management. J Otolaryngol Head Neck Surg. 2016;45(3):1-7.
46.
RehDDHurKMerloCA. Efficacy of a topical sesame/rose geranium oil compound in patients with hereditary hemorrhagic telangiectasia associated epistaxis. Laryngoscope. 2013;123(4):820–822.
47.
BoyerHFernandesPDuranOHunterDGodingG. Office-based sclerotherapy for recurrent epistaxis due to hereditary hemorrhagic telangiectasia: A pilot study. Int Forum Allergy Rhinol. 2011;1(4):319–323.
48.
BoyerHFernandesPLeCYuehB. Prospective randomized trial of sclerotherapy vs standard treatment for epistaxis due to hereditary hemorrhagic telangiectasia. Int Forum Allergy Rhinol. 2015;5(5):435–440.
49.
FranchiniMLippiG. Thalidomide for hereditary haemorrhagic telangiectasia. Lancet Haematol. 2015;2(11):e457–e458.
50.
OlitskySE. Topical timolol for the treatment of epistaxis in hereditary hemorrhagic telangiectasia. Am J Otolaryngol. 2012;33(3):375–376.
51.
EpperlaNBrilliantMHVidailletH. Topical timolol for treatment of epistaxis in hereditary haemorrhagic telangiectasia associated with bradycardia: a look at CYP2D6 metabolising variants. BMJ Case Rep. 2014;2014(1):1-3.
52.
LebrinFSrunSRaymondK, et al.Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med. 2010;16(4):420–428.
53.
PenalozaAVekemansM-CLambertCHermansC. Deep vein thrombosis induced by thalidomide to control epistaxis secondary to hereditary haemorrhagic telangiectasia. Blood Coagul Fibrinolysis. 2011;22(7):616–618.
54.
VasePLorentzenM. Histological findings following oestrogen treatment of hereditary haemorrhagic telangiectasia. A controlled double-blind investigation. J Laryngol Otol. 1983;97(5):427–429.
55.
HarrisonLKundraAJervisP. The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia: Systematic review. J Laryngol Otol. 2018;132(10):866–871.
56.
JamesonJJCaveDR. Hormonal and antihormonal therapy for epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope. 2004;114(4):705–709.
KhanwalkarARRathorAReadAKPaknezhadHMaYHwangPH. Randomized, controlled, double-blinded clinical trial of effect of bevacizumab injection in management of epistaxis in hereditary hemorrhagic telangiectasia patients undergoing surgical cauterization. Int Forum Allergy Rhinol.2022;12(8):1034–1042.
59.
ChenHZhangZChenX, et al.Meta-analysis of efficacy and safety of bevacizumab in the treatment of hereditary hemorrhagic telangiectasia epistaxis. Front Pharmacol. 2023;14(1): 1089847.
60.
SimondsJMillerFMandelJDavidsonTM. The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope. 2009;119(5):988–992.
61.
KarnezisTTDavidsonTM. Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope. 2011;121(3):636–638.
62.
KarnezisTTDavidsonTM. Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy. Laryngoscope. 2012;122(3):495–497.
63.
RissDBurianMWolfAKranebitterVKaiderAArnoldnerC. Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: A double-blind, randomized, placebo-controlled trial. Head Neck. 2015;37(6):783–787.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
